Exagen (XGN)

• Market cap: $67.3M
• 1 day: 4.74%
• 5 days: -2.59%
• 1 month: 22.88%
• 3 months: 21.68%
• 6 months: 31.93%
• Year to date: 21.68%
• 1 year: 139.49%
• 5 years: -73.93%
• 10 years: -79.76%
• Sector: Healthcare
• Industry: Medical Laboratories

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

200% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 3

25% more capital invested

Capital invested by funds: $19.8M [Q3] → $24.8M (+$5.01M) [Q4]

18% more funds holding

Funds holding: 34 [Q3] → 40 (+6) [Q4]

2.52% less ownership

Funds ownership: 36.77% [Q3] → 34.25% (-2.52%) [Q4]

43% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 14

81% less call options, than puts

Call options by funds: $5K | Put options by funds: $26K

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $7 86% upside
• Avg. target: $7.50 99% upside
• High target: $8 113% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Cantor Fitzgerald Ross Osborn 33% 1-year accuracy 15 / 46 met price target	113% upside $8	Overweight Reiterated	13 Jan 2025
Canaccord Genuity Kyle Mikson 33% 1-year accuracy 9 / 27 met price target	86% upside $7	Buy Maintained	3 Jan 2025